Literature DB >> 22187341

Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study.

Gan You1, Zhi-Yi Sha, Wei Yan, Wei Zhang, Yong-Zhi Wang, Shao-Wu Li, Lin Sang, Zi Wang, Gui-Lin Li, Shou-Wei Li, Yi-Jun Song, Chun-Sheng Kang, Tao Jiang.   

Abstract

Seizure is a common presenting manifestation and plays an important role in the clinical presentation and quality of life for patients with low-grade gliomas (LGGs). The authors set out to identify factors that influence preoperative seizure characteristics and postoperative seizure control. Cases involving adult patients who had undergone initial surgery for LGGs in a single institution between 2005 and 2009 were retrospectively reviewed. Univariate and multivariate logistic regression analyses were used to identify factors associated with preoperative seizures and postoperative seizure control. Of the 508 patients in the series, 350 (68.9%) presented with seizures. Age less than 38 years and cortical involvement of tumor were more likely to be associated with seizures (P = .003 and .001, respectively, multivariate logistic analysis). For the cohort of 350 patients with seizures, Engel classification was used to evaluate 6- and 12-month outcome after surgery: completely seizure free (Engel class I), 65.3% and 62.5%; not seizure free (Engel classes II, III, IV), 34.7% and 37.5%. After multivariate logistic analysis, favorable seizure prognosis was more common in patients with secondary generalized seizure (P = .006) and with calcification on MRI (.031). With respect to treatment-related variables, patients achieved much better seizure control after gross total resection than after subtotal resection (P < .0001). Ki67 was an independent molecular marker predicting poor seizure control in the patients with a history of seizure if overexpressed but was not a predictor for those without preoperative seizures. These factors may provide insight into developing effective treatment strategies aimed at prolonging patients' survival.

Entities:  

Mesh:

Year:  2011        PMID: 22187341      PMCID: PMC3266386          DOI: 10.1093/neuonc/nor205

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  54 in total

1.  Epileptic seizures during follow-up of patients treated for primary brain tumors.

Authors:  Jerzy Hildebrand; Cristel Lecaille; Joëlle Perennes; Jean-Yves Delattre
Journal:  Neurology       Date:  2005-07-26       Impact factor: 9.910

2.  Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas.

Authors:  Michèle Kujas; Julie Lejeune; Alexandra Benouaich-Amiel; Emmanuelle Crinière; Florence Laigle-Donadey; Yannick Marie; Karima Mokhtari; Marc Polivka; Michèle Bernier; Fabrice Chretien; Anne Couvelard; Laurent Capelle; Hugues Duffau; Philippe Cornu; Philippe Broët; Joëlle Thillet; Antoine F Carpentier; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  Ann Neurol       Date:  2005-08       Impact factor: 10.422

3.  Epilepsy and gliomas: incidence and treatment in 119 patients.

Authors:  A Pace; L Bove; P Innocenti; A Pietrangeli; C M Carapella; P Oppido; L Raus; E Occhipinti; B Jandolo
Journal:  J Exp Clin Cancer Res       Date:  1998-12

Review 4.  Epidemiology and etiology of gliomas.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2005-02-01       Impact factor: 17.088

5.  Glioma cells release excitotoxic concentrations of glutamate.

Authors:  Z C Ye; H Sontheimer
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

Review 6.  Influences of brain tumor-associated pH changes and hypoxia on epileptogenesis.

Authors:  B Schaller
Journal:  Acta Neurol Scand       Date:  2005-02       Impact factor: 3.209

7.  Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase.

Authors:  John K Wiencke; Kenneth Aldape; Alex McMillan; Joe Wiemels; Michelle Moghadassi; Rei Miike; Karl T Kelsey; Joe Patoka; Jeff Long; Margaret Wrensch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-07       Impact factor: 4.254

8.  Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.

Authors:  Marta Brell; Avelina Tortosa; Eugenia Verger; Juan Miguel Gil; Nuria Viñolas; Salvador Villá; Juan José Acebes; Lluis Caral; Teresa Pujol; Isidro Ferrer; Teresa Ribalta; Francesc Graus
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

9.  Prevalence and prognostic significance of epilepsy in patients with gliomas.

Authors:  K Lote; A E Stenwig; K Skullerud; H Hirschberg
Journal:  Eur J Cancer       Date:  1998-01       Impact factor: 9.162

10.  Prognosis of epilepsy associated with single CT enhancing lesion: a long term follow up study.

Authors:  J M Murthy; Y V Subba Reddy
Journal:  J Neurol Sci       Date:  1998-08-14       Impact factor: 3.181

View more
  45 in total

Review 1.  Seizures in oligodendroglial tumors.

Authors:  Melissa Kerkhof; Christa Benit; Alberto Duran-Pena; Charles J Vecht
Journal:  CNS Oncol       Date:  2015-10-19

2.  A better surgical resectability of WHO grade II gliomas is independent of favorable molecular markers.

Authors:  Dominik Cordier; Catherine Gozé; Sabine Schädelin; Valérie Rigau; Luigi Mariani; Hugues Duffau
Journal:  J Neurooncol       Date:  2014-09-28       Impact factor: 4.130

3.  Whole exome-wide association study identifies a missense variant in SLC2A4RG associated with glioblastoma risk.

Authors:  Yingjie Zhao; Dapeng Yun; Xiang Zou; Tao Jiang; Gang Li; Lingna Hu; Juxiang Chen; Jianfeng Xu; Ying Mao; Hongyan Chen; Daru Lu
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

Review 4.  Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review.

Authors:  Johan A F Koekkoek; Melissa Kerkhof; Linda Dirven; Jan J Heimans; Jaap C Reijneveld; Martin J B Taphoorn
Journal:  Neuro Oncol       Date:  2015-03-25       Impact factor: 12.300

Review 5.  Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments.

Authors:  Roberta Rudà; Lorenzo Bello; Hugues Duffau; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

6.  Cortical hemosiderin is associated with seizures in patients with newly diagnosed malignant brain tumors.

Authors:  Ulrich Roelcke; Larissa Boxheimer; Ali Reza Fathi; Lucia Schwyzer; Marcos Ortega; Jatta Berberat; Luca Remonda
Journal:  J Neurooncol       Date:  2013-09-18       Impact factor: 4.130

7.  What is New in the Management of Epilepsy in Gliomas?

Authors:  Roberta Rudà; Riccardo Soffietti
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

Review 8.  Incidental diffuse low-grade gliomas: from early detection to preventive neuro-oncological surgery.

Authors:  Guilherme Lucas de Oliveira Lima; Marc Zanello; Emmanuel Mandonnet; Luc Taillandier; Johan Pallud; Hugues Duffau
Journal:  Neurosurg Rev       Date:  2015-11-27       Impact factor: 3.042

9.  Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution.

Authors:  Pei Yang; Yongzhi Wang; Xiaoxia Peng; Gan You; Wei Zhang; Wei Yan; Zhaoshi Bao; Yinyan Wang; Xiaoguang Qiu; Tao Jiang
Journal:  J Neurooncol       Date:  2013-03-13       Impact factor: 4.130

Review 10.  Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.

Authors:  Edward K Avila; Marc Chamberlain; David Schiff; Jaap C Reijneveld; Terri S Armstrong; Roberta Ruda; Patrick Y Wen; Michael Weller; Johan A F Koekkoek; Sandeep Mittal; Yoshiki Arakawa; Ali Choucair; Jorge Gonzalez-Martinez; David R MacDonald; Ryo Nishikawa; Aashit Shah; Charles J Vecht; Paula Warren; Martin J van den Bent; Lisa M DeAngelis
Journal:  Neuro Oncol       Date:  2016-09-20       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.